{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Acasti Pharma, Inc. technically bullish or bearish?
As of June 9, 2025, Acasti Pharma, Inc. shows a mildly bullish trend supported by the weekly and monthly MACD, KST, and Bollinger Bands, despite mixed signals from daily moving averages.
Who are in the management team of Acasti Pharma, Inc.?
As of March 2022, Acasti Pharma, Inc.'s management team includes Dr. Roderick Carter as Independent Chairman, Ms. Janelle D'Alvise as President and CEO, and Independent Directors Mr. Jean-Marie Canan and Mr. Donald Olds.
What does Acasti Pharma, Inc. do?
Acasti Pharma, Inc. is a biopharmaceutical company specializing in the development of prescription drugs using omega-3 fatty acids from krill oil. It operates as a micro-cap company with a market cap of approximately $39.23 million and reported a net profit loss of $4 million in December 2024.
How big is Acasti Pharma, Inc.?
As of Jun 18, Acasti Pharma, Inc. has a market capitalization of 39.23 million, with net sales of 0.00 million and a net profit of -13.38 million over the latest four quarters. The company reported shareholder's funds of 61.74 million and total assets of 73.30 million as of Mar 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
